UnitedHealth Group (NYSE: UNH) delivered a quarter that rewrites the narrative for the year. Adjusted EPS of $6.38 smashed the $4.88 consensus by 31%. Management responded by raising full-year 2026 adjusted EPS guidance to $19.50-$20.00 from a prior floor of $17.75. The new midpoint sits a full $1.00 above the old ceiling.
The headline driver was medical cost performance. The medical care ratio (MCR) came in at 86.7%, down 270 basis points from 89.4% a year ago and well inside the newly narrowed full-year guidance of 88.1% ± 25 bps. The quarter included $860 million in net favorable prior period development. Even stripping that out, the underlying MCR was materially better than the 89.4% print in Q2 2025. Management credited benefit design changes, pricing discipline, and member mix shifts. The improvement looks structural rather than cyclical: the company narrowed its full-year MCR guidance range from ±50 bps to ±25 bps, signaling confidence that the lower cost trend is sustainable.
UnitedHealthcare operating margin doubled to 4.6% from 2.4% a year ago. This happened even as total members served declined 525,000 sequentially to 48.5 million. The membership contraction was concentrated in Medicare Advantage (down 965,000 since year-end 2025) and Medicaid (down 380,000 sequentially, partly from the planned Louisiana exit). Revenue was essentially flat at $86.0 billion. The margin improvement came from pricing discipline and medical cost management, not volume growth. A business getting more profitable on a smaller base.
Optum posted 160 bps of margin expansion to 6.2%. Optum Health swung to a 5.1% margin from 1.7% a year ago. That turnaround came despite a 5% revenue decline and roughly 700,000 fewer value-based care patients served. The improvement was driven by operational improvements and medical cost management. Optum Insight earnings rose to $1.4 billion from $1.2 billion, helped by contract timing. Optum Rx earnings edged up to $1.5 billion on specialty generics adoption, though adjusted scripts fell to 387 million from 414 million on membership declines.
Cash flow was the other standout. Operating cash flow hit $11.1 billion in the quarter, or 1.9x net income, helped by a substantial government payment and disciplined working capital. Full-year operating cash flow guidance was raised to ~$24 billion from >$18 billion, a $6 billion increase. The company repurchased $4.0 billion of stock through mid-July and raised the full-year buyback target to at least $5.0 billion from ~$2.5 billion. The buyback pace looks aggressive given the stock's valuation, but the cash flow supports it.
The company also detailed a sweeping set of strategic reforms: a $1 billion United Health Foundation commitment, elimination of 30% of prior authorizations, a new transparent PBM model, and voluntary elimination of ACA profits in 2026. These moves address regulatory and public scrutiny head-on. They also carry near-term costs. The operating cost ratio ticked up to 12.7% from 12.3% on targeted investments in technology and community support.
The guidance raise is the clearest signal. Full-year adjusted EPS guidance of $19.50-$20.00 implies second-half adjusted EPS of roughly $5.89-$6.39, below the $6.38 Q2 print but above the $4.08 reported in Q2 2025. The implied second-half deceleration from Q2's beat is conservative. The full-year raise is substantial enough to suggest management sees the cost trends as durable. The narrowed MCR guidance range reinforces that view.
What to watch next: whether UnitedHealthcare can sustain margin expansion as membership continues to contract, and whether Optum Health's margin recovery can hold as it recenters on a smaller patient base. The cash flow trajectory is the strongest signal of underlying health. At the new guidance midpoint, UNH trades at roughly 19x forward adjusted EPS, a discount to its historical multiple that the quarter's results may begin to close.